Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology

Pudil, Radek; Mueller, Christian; Čelutkienė, Jelena; Henriksen, Peter; Lenihan, Dan; Dent, Susan; Barac, Ana; Stanway, Susanna; J. Moslehi, Javid; Suter, Thomas; Ky, Bonnie; Štěrba, Martin; Cardinale, Daniela; Cohen‐Solal, Alain; G. Tocchetti, Carlo; Farmakis, Dimitrios; Bergler‐Klein, Jutta; S. Anker, Markus; von Haehling, Stephan; N. Belenkov, Yu.; Iakobishvili, Zaza; Maack, Christoph; Ciardiello, Fortunato; Ruschitzka, Frank; J.S. Coats, Andrew; Seferović, Petar; Lainščak, Mitja; Piepoli, Massimo; Chioncel, Ovidiu; Bax, Jereon; Hulot, Jean‐Sébastien; Skouri, Hadi; Haegler‐Laube, Eva; Asteggiano, Riccardo; López‐Fernández, Teresa; A. de Boer, Rudolf; R Lyon, Alexander

doi:10.1002/ejhf.2017

Public

Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology

Published in European Journal of Heart Failure • Oct 2, 2020

Authors:

Radek Pudil

Christian Mueller

Jelena Čelutkienė

Abstract

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprot...

Subject

Medicine

Cardiotoxicity

Trastuzumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!